PPI Side Effects: What You Need to Know
While observational studies have raised concerns about numerous adverse effects from long-term PPI use, randomized controlled trials have not demonstrated increased rates of serious adverse events compared to placebo, and the decision to discontinue PPIs should be based solely on lack of indication—not fear of side effects 1.
The Evidence Paradox
The 2022 AGA guidelines emphasize a critical distinction: observational studies have linked PPIs to multiple adverse outcomes including chronic kidney disease, fractures, dementia, and COVID-19, but none of these associations establish causality 1. In stark contrast, RCTs comparing PPIs with placebo show no higher rate of any adverse event among PPI users 1. This discrepancy suggests that confounding factors—not the PPIs themselves—likely explain many reported associations.
Short-Term Side Effects
Common and Generally Mild
The FDA-approved labels document the most frequent short-term effects 2, 3:
In adults:
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Vomiting
- Gas
- Dizziness
- Joint pain
In adolescents:
- Upper respiratory infection
- Headache
- Fever
- Diarrhea
- Vomiting
- Rash
- Abdominal pain
Rebound Acid Hypersecretion
Patients discontinuing long-term PPI therapy will likely develop transient upper GI symptoms due to rebound acid hypersecretion 1. This is a predictable physiological response, not a true adverse effect, but patients must be counseled about it to prevent unnecessary resumption of therapy.
Long-Term Risks: What's Actually Proven
High Probability of Causality
1. Gastrointestinal Infections The strongest evidence supports increased risk of enteric infections 4, 5, 6. Decreased gastric acidity allows bacterial overgrowth, leading to:
- Clostridium difficile infection
- Community-acquired pneumonia
- Salmonella and Campylobacter infections 7
2. Micronutrient Deficiencies
Vitamin B12 deficiency occurs in patients taking PPIs for more than 3 years 2, 3. Watch for:
- Shortness of breath
- Lightheadedness
- Irregular heartbeat
- Muscle weakness
- Pale skin
- Fatigue
- Mood changes
- Tingling or numbness in extremities
Hypomagnesemia develops after at least 3 months of therapy 2, 3. Monitor for:
- Seizures
- Dizziness
- Irregular heartbeat
- Jitteriness
- Muscle aches or weakness
- Spasms of hands, feet, or voice
Hypocalcemia and iron deficiency are also documented 4, 8.
3. Fundic Gland Polyps Long-term PPI use (especially >1 year) increases risk of these benign stomach growths 2, 3. While generally not dangerous, they require awareness.
Moderate Evidence (Observational Data)
Kidney Disease: Multiple observational studies link PPIs to acute interstitial nephritis, acute kidney injury, chronic kidney disease, and end-stage renal disease 4, 5. However, the causality remains unproven.
Bone Fractures: Associations with hip, wrist, and spine fractures have been reported, particularly with higher doses and longer duration 4, 5, 8. The mechanism may involve impaired calcium absorption.
Cardiovascular Events: Some studies suggest increased risk of myocardial infarction, stroke, and major adverse cardiovascular events 4. Critical drug interaction: PPIs may reduce clopidogrel effectiveness, potentially increasing cardiovascular risk 8.
Controversial/Weak Evidence
Dementia and Depression: Observational studies suggest associations 4, 9, 10, but these are highly susceptible to confounding. Patients with chronic GI symptoms may have underlying conditions predisposing to both PPI use and psychiatric disorders.
Cancer: Links to gastric, pancreatic, colorectal, and hepatic cancers have been proposed 4, 8, likely related to hypergastrinemia from chronic acid suppression. However, causality is not established.
Mortality: Recent studies show associations with all-cause mortality 11, but again, confounding by indication (sicker patients receive PPIs) cannot be excluded.
Critical Clinical Guidance
When NOT to Worry About Side Effects
The AGA is explicit: The presence of a PPI-associated adverse event or risk factors for adverse events is NOT an independent indication for PPI withdrawal 1. If a patient has a legitimate indication (complicated GERD, Barrett's esophagus, high GI bleeding risk, eosinophilic esophagitis, idiopathic pulmonary fibrosis), continue the PPI regardless of side effect concerns.
When to Consider De-prescribing
De-prescribe based on lack of indication only, not fear of adverse effects 1. Appropriate candidates:
- Patients without definitive indication for chronic PPI
- Those on twice-daily dosing who could step down to once-daily
- Patients with nonerosive GERD who may not need continuous therapy
Monitoring Strategy
For patients requiring long-term PPI therapy:
- Check magnesium levels if on therapy ≥3 months, especially in patients taking diuretics or digoxin 2, 3
- Assess vitamin B12 if on therapy >3 years 2, 3
- Monitor for warfarin interaction if co-prescribed—increased bleeding risk requires INR monitoring 3
- Avoid rilpivirine-containing HIV regimens (absolute contraindication) 2
Common Pitfalls to Avoid
Don't discontinue PPIs in patients with clear indications due to fear of poorly proven side effects 1, 6. The risk of untreated acid-related disease (bleeding, stricture, Barrett's progression) far outweighs theoretical long-term risks.
Don't ignore rebound symptoms as treatment failure. Counsel patients that transient symptoms after discontinuation are expected and will resolve 1.
Don't assume all reported associations are causal. The highest quality evidence (RCTs) does not support most feared complications 1.
Don't forget drug interactions: Particularly with clopidogrel, methotrexate, digoxin, and warfarin 2, 3.
Bottom Line for Practice
PPIs remain safe and appropriate for patients with legitimate indications 1. The most important safety issue is critically evaluating the indication at initiation and regularly reassessing the need for continued therapy 6. Worry about poorly proven side effects should not lead to unnecessary discontinuation in patients who benefit from treatment.